Windlas Biotech's Whole-time Director resigns; Hitesh Windlass made Chairman
- Management change
- Pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Windlas Biotech (NSE: WINDLAS) has accepted the resignation of Ashok Kumar Windlass as Whole-time Director and Director, effective 5 Nov 2026, and appointed Hitesh Windlass as Chairman, it said in a filing on 05 Nov 2026. Ashok Kumar Windlass is to become Founder President, Senior Management Personnel, at fixed remuneration of ₹1.56 crore a year.
Key highlights
- ,
- Resignation effective: 5 Nov 2026 at 10.00 A.M.
- Founder President appointment effective: 6 Nov 2026
- Founder President pay: ₹1.56 crore a year, no increase
- Hitesh Windlass: Chairman from 5 Nov 2026, also Managing Director
The board changes in numbers
| Item | Detail |
|---|---|
| Officer resigning | Ashok Kumar Windlass, Whole-time Director and Director |
| Resignation effective | 5 Nov 2026 at 10.00 A.M. |
| Reason given | Long-term succession planning |
| New role | Founder President, Senior Management Personnel, effective 6 Nov 2026, subject to shareholder approval |
| Fixed remuneration | ₹1.56 crore a year, without increase over his Whole-time Director pay |
| Chairman appointed | Hitesh Windlass, from 5 Nov 2026, in addition to his role as Managing Director |
The resignation and the succession plan
The board accepted the resignation of Ashok Kumar Windlass from the posts of Whole-time Director and Director with effect from 5 Nov 2026 at 10.00 A.M. The company says the resignation is due to its long-term succession planning, and his letter states there are no other material reasons beyond those stated.
He also ceases to be a member of the Corporate Social Responsibility Committee. The filing describes him as Promoter and Founder of the company.
A founder role and a chairman
The board, on the recommendation of the Nomination and Remuneration Committee and the Audit Committee, approved his appointment as Founder President, Senior Management Personnel, effective 6 Nov 2026, subject to shareholder approval. The filing says shareholder approval would constitute an appointment to an office or place of profit under Section 188(1)(f) of the Companies Act, 2013.
Hitesh Windlass, Managing Director and Promoter, was appointed Chairman of the Board from 5 Nov 2026. Each holds 44,00,000 shares, according to Annexure III.
The company's latest quarter, Q1 FY27 standalone, showed total income of ₹253.21 crore, up 17.6% year on year. The filing's own results for the quarter ended 30 Sep 2026 were approved at the same meeting.
What the board changes mean for Windlas Biotech's shareholders
The changes put the founder into a senior management role at a fixed salary of ₹1.56 crore a year, and make Hitesh Windlass Chairman as well as Managing Director. The founder's new role takes effect only after shareholders approve it.
The filing does not say who replaces Ashok Kumar Windlass as Whole-time Director, what the Founder President role involves, or whether shareholders have approved it. The next dated step is the shareholder vote on his appointment.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
